以色列 - 希伯来文 - Ministry of Health

merck sharp & dohme israel ltd - interferon alfa 2b 18 miu/ml - solution for injection - interferon alfa-2b - chronic hepatitis b, chronic hepatitis c, hairy cell leukemia, chronic myelogenous leukemia, aids related kaposi`s sarcoma, malignant melanoma.treatment of metastatic or recurrent renal cell carcinoma non hodgkin`s lymphoma. treatment of high tumour burden follicular lymphoma as adjunct to apropriate combination induction chemotherapy such as a chop like regimen.

以色列 - 希伯来文 - Ministry of Health

merck sharp & dohme israel ltd - peginterferon alfa 2b 80 mcg / 0.5 ml - powder for solution for injection - interferon alfa-2b - peg- intron is indicated for the treatment of adult patients with histologically proven chronic hepatitis c who have elevated transaminases without liver decompensation and who are positive for serum hcv-rna or anti-hcv including naive patients with clinically stable hiv coinfection. the best way to use peg- intron in this indication is in combination with ribavirin. this combination is indicated in naive patients including patients with clinically stable hiv co-infection and in patients who have failed previous treatment with interferon alpha (pegylated or nonpegylated ) and ribavirin combination therapy or interferon alpha monotherapy. interferon monotherapy including peg-intron is indicated mainly in case of intolerance or contraindication to ribavirin. please refer also to the ribavirin physician's insert when pegintron is to be used in combination with ribavirin.

以色列 - 希伯来文 - Ministry of Health

merck sharp & dohme israel ltd - interferon alfa 2b 10 miu - solution for injection - interferon alfa-2b - - chronic hepatitis b. - chronic hepatitis c. - hairy cell leukaemia. - chronic myelogenous leukaemia. - multiple myeloma. - folicular lymphoma. - carcinoid tumour. - malignant melanoma.

以色列 - 希伯来文 - Ministry of Health

merck sharp & dohme israel ltd - peginterferon alfa 2b 100 mcg / 0.5 ml - powder for solution for injection - peginterferon alfa-2b - peg- intron is indicated for the treatment of adult patients with histologically proven chronic hepatitis c who have elevated transaminases without liver decompensation and who are positive for serum hcv-rna or anti-hcv including naive patients with clinically stable hiv coinfection. the best way to use peg- intron in this indication is in combination with ribavirin. this combination is indicated in naive patients including patients with clinically stable hiv co-infection and in patients who have failed previous treatment with interferon alpha (pegylated or nonpegylated ) and ribavirin combination therapy or interferon alpha monotherapy. interferon monotherapy including peg-intron is indicated mainly in case of intolerance or contraindication to ribavirin. please refer also to the ribavirin physician's insert when pegintron is to be used in combination with ribavirin.

以色列 - 希伯来文 - Ministry of Health

merck sharp & dohme israel ltd - peginterferon alfa 2b 120 mcg / 0.5 ml - powder for solution for injection - peginterferon alfa-2b - peg- intron is indicated for the treatment of adult patients with histologically proven chronic hepatitis c who have elevated transaminases without liver decompensation and who are positive for serum hcv-rna or anti-hcv including naive patients with clinically stable hiv coinfection. the best way to use peg- intron in this indication is in combination with ribavirin. this combination is indicated in naive patients including patients with clinically stable hiv co-infection and in patients who have failed previous treatment with interferon alpha (pegylated or nonpegylated ) and ribavirin combination therapy or interferon alpha monotherapy. interferon monotherapy including peg-intron is indicated mainly in case of intolerance or contraindication to ribavirin. please refer also to the ribavirin physician's insert when pegintron is to be used in combination with ribavirin.

以色列 - 希伯来文 - Ministry of Health

roche pharmaceuticals (israel) ltd - peginterferon alfa 2a 135 mcg / 0.5 ml - solution for injection - peginterferon alfa-2a - chronic hepatitis b: pegasys is indicated for the treatment of both hbeag- positive and hbeag -negative chronic hepatitis b in non-cirrhotic and cirrhotic adult patients with compensated liver disease and evidence of viral replication and liver inflammation.chronic hepatitis c: pegasys is indicated for the treatment of chronic hepatitis c in adult patients who are positive for serum hcv-rna including patients with compensated cirrhosis and/or co-infected with clinically stable hiv. the optimal way to use pegasys in patients with chronic hepatitis c is in combination with ribavirin. the combination of pegasys and ribavirin is indicated in naive patients and patients who have failed previous treatment with interferon alpha (pegylated or non-pegylated ) alone or in combination therapy with ribavirin. monotherapy is indicated mainly in case of intolerance or contraindication to ribavirin.

以色列 - 希伯来文 - Ministry of Health

roche pharmaceuticals (israel) ltd - peginterferon alfa 2a 180 mcg / 0.5 ml - solution for injection - peginterferon alfa-2a - chronic hepatitis b: pegasys is indicated for the treatment of both hbeag- positive and hbeag -negative chronic hepatitis b in non-cirrhotic and cirrhotic adult patients with compensated liver disease and evidence of viral replication and liver inflammation.chronic hepatitis c: pegasys is indicated for the treatment of chronic hepatitis c in adult patients who are positive for serum hcv-rna including patients with compensated cirrhosis and/or co-infected with clinically stable hiv. the optimal way to use pegasys in patients with chronic hepatitis c is in combination with ribavirin. the combination of pegasys and ribavirin is indicated in naive patients and patients who have failed previous treatment with interferon alpha (pegylated or non-pegylated ) alone or in combination therapy with ribavirin. monotherapy is indicated mainly in case of intolerance or contraindication to ribavirin.

以色列 - 希伯来文 - Ministry of Health

novartis israel ltd - ciclosporin - תמיסה לאינפוזיה - ciclosporin 50 mg/ml - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation.

以色列 - 希伯来文 - Ministry of Health

novartis israel ltd - ciclosporin - קפסולות - ciclosporin 50 mg - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that did not respond to other treatment. atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis: severe cases in which standard treatments are ineffective or inappropriate. nephrotic syndrom type mcd (minimal change disease) in cases where conventional therapy has failed.

以色列 - 希伯来文 - Ministry of Health

novartis israel ltd - ciclosporin - קפסולות - ciclosporin 100 mg - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that did not respond to other treatment. atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis: severe cases in which standard treatments are ineffective or inappropriate. nephrotic syndrom type mcd (minimal change disease) in cases where conventional therapy has failed.